Jim Simons
URGN icon

Jim Simons’s UroGen Pharma URGN Stock Holding History

Jim Simons’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
+70,300
New +$1.91M ﹤0.01% 1824
2026
Q1 		– Sell
-244,300
Closed -$5.72M – 3708
2025
Q4 		$5.72M Sell
244,300
-30,800
-11% -$668K 0.01% 1218
2025
Q3 		$5.49M Buy
275,100
+236,900
+620% +$4.25M 0.01% 1435
2025
Q2 		$523K Sell
38,200
-52,400
-58% -$503K ﹤0.01% 2803
2025
Q1 		$1M Sell
90,600
-47,600
-34% -$507K ﹤0.01% 2432
2024
Q4 		$1.47M Buy
+138,200
New +$1.65M ﹤0.01% 2255
2024
Q1 		– Sell
-91,300
Closed -$1.37M – 4103
2023
Q4 		$1.37M Sell
91,300
-69,000
-43% -$896K ﹤0.01% 2200
2023
Q3 		$2.25M Buy
160,300
+86,300
+117% +$1.39M ﹤0.01% 1788
2023
Q2 		$766K Buy
74,000
+26,000
+54% +$287K ﹤0.01% 2635
2023
Q1 		$444K Buy
48,000
+4,700
+11% +$43.3K ﹤0.01% 2943
2022
Q4 		$384K Buy
43,300
+200
+0.5% +$1.89K ﹤0.01% 3105
2022
Q3 		$359K Sell
43,100
-500
-1% -$4.14K ﹤0.01% 3115
2022
Q2 		$357K Buy
43,600
+18,900
+77% +$130K ﹤0.01% 3354
2022
Q1 		$215K Buy
+24,700
New +$193K ﹤0.01% 3614
2021
Q1 		– Sell
-32,800
Closed -$591K – 3728
2020
Q4 		$591K Buy
+32,800
New +$687K ﹤0.01% 2745
2019
Q2 		– Sell
-8,000
Closed -$296K – 3767
2019
Q1 		$296K Buy
+8,000
New +$335K ﹤0.01% 3098
2018
Q4 		– Sell
-16,800
Closed -$793K – 3629
2018
Q3 		$793K Sell
16,800
-98,651
-85% -$4.58M ﹤0.01% 2697
2018
Q2 		$5.74M Sell
115,451
-41,249
-26% -$2.4M 0.01% 1699
2018
Q1 		$7.79M Buy
156,700
+25,600
+20% +$1.28M 0.01% 1530
2017
Q4 		$4.88M Buy
131,100
+105,500
+412% +$3.76M 0.01% 1824
2017
Q3 		$807K Buy
+25,600
New +$565K ﹤0.01% 2645

Other funds holding URGN

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jim Simons's URGN Position: Q2 2026 in Review

Jim Simons opened a new position in UroGen Pharma (URGN) in Q2 2026: 70,300 shares worth $2.59M. The stake represents ﹤0.01% of the portfolio and ranks #1824 among its holdings. This is a return to the name: Jim Simons previously reported a position in URGN as recently as Q4 2025.

Jim Simons first reported a position in URGN in Q3 2017 and has held it in 21 quarters since. The position peaked at $7.79M in Q1 2018. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jim Simons held 70,300 shares of UroGen Pharma worth $2.59M as of Q2 2026.
  • UroGen Pharma was a new Jim Simons position in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1824 holding.
  • Jim Simons first reported a position in UroGen Pharma in Q3 2017 and has held it in 21 quarters since.
  • Jim Simons's UroGen Pharma position peaked at $7.79M in Q1 2018.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.